# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target f...
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target f...
Needham analyst Mike Matson reiterates Haemonetics (NYSE:HAE) with a Hold.
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.
This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adu...